GABA-glutamate Interactions and Psychosis

Phase 1

Completed

• Conditions: Cognitive Dysfunction
• Interventions: Drug: iomazenil

• Registration Number: NCT00611572
• Lead Sponsor: Yale University

Brief Summary

This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-01
• Study First Submitted: 2008-01-29
• Study First Submitted QC: 2008-01-29
• Study First Posted: 2008-02-11
• Primary Completion: 2018-10-02
• Study Completion: 2018-10-02
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-21
• Last Update Posted: 2022-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
2	iomazenil	placebo iomazenil and ketamine
1	iomazenil	Active iomazenil and ketamine

Primary Outcome Measures

Name	Time	Method
P300 as an ERP measure	prospective

Secondary Outcome Measures

Name	Time	Method
MMN (Mismatch Negativity)	prospective

Trial Locations

Locations (1)

VHA Connecticut; 🇺🇸 West Haven, Connecticut, United States